---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-25-000047"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:30:32.099655+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised

## Summary
- GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).
- Launch products LEQEMBI ($121M, +82%), SKYCLARYS ($133M, +30%), ZURZUVAE ($55M) all show strong growth.
- Full year 2025 revenue guidance raised to flat to +1% (constant currency); Non-GAAP EPS guided $14.50-$15.00.
- Pipeline: LEQEMBI IQLIK approved, high-dose nusinersen resubmitted (PDUFA Apr'26), litifilimab Phase 3 fully enrolled (data H2'26).

## SEC filing metadata
- accession: 0000875045-25-000047
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/0000875045-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/biib-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-25-000047
- JSON: https://secwatch.observer/filing/0000875045-25-000047.json
- Plain text: https://secwatch.observer/filing/0000875045-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.